(UroToday.com) The genetic landscape of bladder cancer has been generally poorly examined, compared for example with prostate cancer. However, there are intriguing emerging data that suggest that many patients with locally advanced and metastatic urothelial cancer harbor rare germline variants in cancer predisposition genes, including in DNA damage response (DDR) genes. This, however, has not been thoroughly studied in patients with non-muscle invasive bladder cancer (NMIBC), who represent the vast majority of patients newly diagnosed with bladder cancer. In a podium presentation at the American Urological Association (AUA) 2020 Virtual Meeting, Dr. Pietzak and colleagues presented results of a prospectively accrued cohort of patients with non-muscle invasive bladder cancer who were examined for germline variant in cancer predisposition genes.